"The process of declaring parts of aging as a disease is driven by regulation: the FDA does not permit treatments for aging, only for named diseases. Since there is little funding for research that cannot be legally commercialized, the incentive is to carve off chunks of the process of aging and go through the process of having government employees add it to the list of diseases - which can take years and millions of dollars. Sarcopenia, for example, is still not recognized by the FDA, meaning that no potential treatment can be commercially developed in the US. Here is an example of this process at work for memory loss."